Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more
Genmab AS - Asset Resilience Ratio
Genmab AS (GMAB) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Genmab AS's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genmab AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Genmab AS maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Genmab AS Industry Peers by Asset Resilience Ratio
Compare Genmab AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Genmab AS (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Genmab AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $81.86 Billion | -- |
| 2024-12-31 | 24.54% | $11.24 Billion | $45.81 Billion | -13.06pp |
| 2023-12-31 | 37.60% | $13.27 Billion | $35.29 Billion | -3.67pp |
| 2022-12-31 | 41.27% | $12.43 Billion | $30.12 Billion | -0.88pp |
| 2021-12-31 | 42.15% | $10.38 Billion | $24.63 Billion | +0.44pp |
| 2020-12-31 | 41.71% | $8.82 Billion | $21.14 Billion | -7.28pp |
| 2019-12-31 | 48.99% | $7.42 Billion | $15.14 Billion | -16.88pp |
| 2018-12-31 | 65.87% | $5.57 Billion | $8.46 Billion | +4.15pp |
| 2017-12-31 | 61.72% | $4.08 Billion | $6.60 Billion | -7.29pp |
| 2016-12-31 | 69.01% | $3.61 Billion | $5.24 Billion | +1.89pp |
| 2015-12-31 | 67.12% | $2.62 Billion | $3.90 Billion | -13.17pp |
| 2014-12-31 | 80.28% | $2.30 Billion | $2.87 Billion | +0.07pp |
| 2013-12-31 | 80.21% | $1.39 Billion | $1.73 Billion | -4.66pp |
| 2012-12-31 | 84.87% | $1.44 Billion | $1.69 Billion | +18.69pp |
| 2011-12-31 | 66.19% | $1.04 Billion | $1.56 Billion | +3.79pp |
| 2010-12-31 | 62.39% | $1.55 Billion | $2.48 Billion | +25.62pp |
| 2009-12-31 | 36.77% | $816.91 Million | $2.22 Billion | -53.20pp |
| 2007-12-31 | 89.97% | $3.56 Billion | $3.96 Billion | +18.20pp |
| 2006-12-31 | 71.77% | $1.30 Billion | $1.80 Billion | +8.18pp |
| 2005-12-31 | 63.60% | $871.56 Million | $1.37 Billion | -- |